Literature DB >> 18402649

Functional gastrointestinal disorders as a public health problem.

N J Talley1.   

Abstract

The functional gastrointestinal disorders (FGIDs) are a heterogeneous group of chronic conditions that are considered to be important to public health because they are remarkably common, can be disabling, and induce a major social and economic burden. Despite the Rome consensus process, the line defining true abnormality from health is as yet imprecise. Furthermore, the concept that the FGIDs have no pathological or biochemical correlates is starting to unravel, and some candidate morphometric abnormalities (e.g. duodenal eosinophilia, colonic mastocytosis) have been documented. The quality of care that patients with FGIDs receive is not well understood, despite the high volume of patients seen in primary and specialty care. There are a remarkable number of symptom-based and disease-based co-morbidities that appear to be more common in those with FGIDs that are not alone explained by coexistent somatization. Whether there is any means of preventing the development of FGIDs post-infection is untested but has vast public health implications. Defining disease severity remains key to better understanding the public health impact of FGIDs; severity is probably influenced by the intestinal and extra-intestinal symptom burden, psychological distress and the impact on quality of life, but how these factors interact remains uncertain. An important future research direction must be to quantify at what risk level it is reasonable to prescribe a medication that may be dangerous, and stratify which subsets of patients with FGIDs would qualify for such an approach using objective well validated tools (e.g. based on accurately defining gradations of severity of disease). Finally, there are some reasons to suspect that there may be an increase in mortality in FGID sufferers; for example, unnecessary surgery or invasive testing has a small but not zero associated mortality, and this should be a factor in view of the high prevalence of disease.

Entities:  

Mesh:

Year:  2008        PMID: 18402649     DOI: 10.1111/j.1365-2982.2008.01097.x

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  77 in total

1.  Irritable bowel syndrome: are complementary and alternative medicine treatments useful?

Authors:  Richard V Birtwhistle
Journal:  Can Fam Physician       Date:  2009-02       Impact factor: 3.275

Review 2.  Mapping and modeling gastrointestinal bioelectricity: from engineering bench to bedside.

Authors:  L K Cheng; P Du; G O'Grady
Journal:  Physiology (Bethesda)       Date:  2013-09

Review 3.  Japanese herbal medicine in functional gastrointestinal disorders.

Authors:  H Suzuki; J M Inadomi; T Hibi
Journal:  Neurogastroenterol Motil       Date:  2009-03-25       Impact factor: 3.598

4.  Multi-Dimensional Gastrointestinal Symptom Severity Index: Validation of a Brief GI Symptom Assessment Tool.

Authors:  Michael D Crowell; Sarah B Umar; Brian E Lacy; Michael P Jones; John K DiBaise; Nicholas J Talley
Journal:  Dig Dis Sci       Date:  2015-04-05       Impact factor: 3.199

5.  Evidence for neuronal and structural changes in submucous ganglia of patients with functional dyspepsia.

Authors:  Carla Cirillo; Talat Bessissow; An-Sofie Desmet; Hanne Vanheel; Jan Tack; Pieter Vanden Berghe
Journal:  Am J Gastroenterol       Date:  2015-06-16       Impact factor: 10.864

6.  Electroceutical Targeting of the Autonomic Nervous System.

Authors:  Charles C Horn; Jeffrey L Ardell; Lee E Fisher
Journal:  Physiology (Bethesda)       Date:  2019-03-01

Review 7.  Medicinal Foods for Functional GI Disorders.

Authors:  Brent W Acker; Brooks D Cash
Journal:  Curr Gastroenterol Rep       Date:  2017-11-13

Review 8.  Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology.

Authors:  Nicholas J Talley; Gerald Holtmann; Marjorie M Walker
Journal:  J Gastroenterol       Date:  2015-04-29       Impact factor: 7.527

9.  The current prevalence of irritable bowel syndrome in Asia.

Authors:  Full-Young Chang; Ching-Liang Lu; Tseng-Shing Chen
Journal:  J Neurogastroenterol Motil       Date:  2010-10-30       Impact factor: 4.924

10.  Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers.

Authors:  Lotta Krogius-Kurikka; Anna Lyra; Erja Malinen; Johannes Aarnikunnas; Jarno Tuimala; Lars Paulin; Harri Mäkivuokko; Kajsa Kajander; Airi Palva
Journal:  BMC Gastroenterol       Date:  2009-12-17       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.